Efavirenz News and Research

RSS
Efavirenz, also known as EFV or Sustiva, is a type of medicine called a non-nucleoside reverse transcriptase inhibitor (NNRTI). NNRTIs block reverse transcriptase, a protein that HIV needs to make more copies of itself. Efavirenz was approved by the FDA on September 17, 1998, for use with other antiretroviral agents in the treatment of HIV infection in adults and children ages 3 and older. This medicine does not cure HIV infection or AIDS and does not reduce the risk of passing the virus to other people. Efavirenz may also be used with other antiretroviral medications to prevent HIV in people who have been exposed to the virus in the work place, such as health care providers who come in contact with HIV infected blood through an accidental needle stick.
Boehringer Ingelheim reports results from SVR12 Phase 3 trial in patients with HCV/HIV co-infection

Boehringer Ingelheim reports results from SVR12 Phase 3 trial in patients with HCV/HIV co-infection

New study explores the effect of food insecurity on treating HIV-infected pregnant women in Uganda

New study explores the effect of food insecurity on treating HIV-infected pregnant women in Uganda

Valproic acid metabolism and obesity: an interview with Dr. Namandjé Bumpus, Johns Hopkins Medicine

Valproic acid metabolism and obesity: an interview with Dr. Namandjé Bumpus, Johns Hopkins Medicine

Merck announces FDA approval of ISENTRESS for oral suspension

Merck announces FDA approval of ISENTRESS for oral suspension

Merck announces approval of NOXAFIL delayed-release tablets by FDA

Merck announces approval of NOXAFIL delayed-release tablets by FDA

FDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection

FDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection

FDA accepts Merck's NOXAFIL IV solution NDA for priority review

FDA accepts Merck's NOXAFIL IV solution NDA for priority review

Gilead Sciences gets marketing authorization from European Commission for Vitekta tablets

Gilead Sciences gets marketing authorization from European Commission for Vitekta tablets

Merck to present pharmacokinetic data on once-daily ISENTRESS at EACS

Merck to present pharmacokinetic data on once-daily ISENTRESS at EACS

More AIDS-defining illnesses and severe side effects occur with appropriate comparator therapy

More AIDS-defining illnesses and severe side effects occur with appropriate comparator therapy

Scientists create polymer additives that enhance orally administered drugs to reach bloodstream

Scientists create polymer additives that enhance orally administered drugs to reach bloodstream

New polymer additives enhance ability of oral drugs to reach bloodstream

New polymer additives enhance ability of oral drugs to reach bloodstream

FDA: New drug Tivicay approved to treat HIV-1 infection

FDA: New drug Tivicay approved to treat HIV-1 infection

Research shows lower daily dose of HIV drug therapy suppresses virus

Research shows lower daily dose of HIV drug therapy suppresses virus

Key HIV drug prices continue to fall, but newer medicines still priced too high

Key HIV drug prices continue to fall, but newer medicines still priced too high

New WHO guidelines recommend earlier treatment for people living with HIV

New WHO guidelines recommend earlier treatment for people living with HIV

FDA approves sNDA for SUSTIVA for treatment of HIV-1 infected pediatric patients

FDA approves sNDA for SUSTIVA for treatment of HIV-1 infected pediatric patients

FDA accepts Merck's NDA for NOXAFIL tablets

FDA accepts Merck's NDA for NOXAFIL tablets

HCV and HIV co-infected patients achieve early treatment success with faldaprevir, PegIFN/RBV

HCV and HIV co-infected patients achieve early treatment success with faldaprevir, PegIFN/RBV

Gilead Sciences fourth quarter total revenues increase 18% to $2.59 billion

Gilead Sciences fourth quarter total revenues increase 18% to $2.59 billion